Intellectual Property

This side-event, organized by the Biotechnology Industry Organization (BIO) and cosponsored by the Association of University Technology Managers (AUTM), provided an overview on the key elements at play in establishment an enabling environment for transfer of technology to support the full implementation of CBD objectives and priorities.

What happens in Washington influences biotechnology progress every bit as much as what happens on Wall Street or in the lab.

The theory claiming that the over-patenting of biotechnology research hinders the research and development of new treatments is not supported by empirical evidence.

Attached please find "Guidelines for BIO members engaging in Bioprospecting". The Guidelines are a set of general principles and practices that BIO, as an organization, believes are appropriate to follow when an entity engages in bioprospecting activities.

Guidelines for The Biotechnology Industry Organization Members Engaging in Bioprospecting

On July 23rd, the House passed by voice vote an amendment on human patenting offered by Dave Weldon (R-Fla.) as part of the Commerce-Justice-State appropriations bill (H.R. 2799).

In the early weeks of the 108th Congress, two Senate bills, S. 54 and S. 7, were introduced that embrace the "Greater Access to Affordable Pharmaceuticals Act of 2003" (GAAP), formerly known in the 107th Congress as S. 812

On October 24th the FDA published proposed regulations that affect implementation of the Hatch-Waxman law. These changes in part respond to recommendations in a July 2002 Federal Trade Commission (FTC) report and a Citizen Petition filed with the FDA by the FTC in May 2001.

Last week, the Senate Health, Education, Labor and Pensions (HELP) Committee marked-up legislation - The Edwards/Collins substitute to S. 812 - The "Greater Access to Affordable Pharmaceuticals Act of 2001" - that raises serious concerns for members of the Biotechnology Industry Organization (BIO).

October 14 2014
The Biotechnology Industry Organization (BIO) appreciates this fifth opportunity to formally respond to the Colombian Ministry of Health’s Draft Decree on Regulatory Requirements for the Registry of Medicines of Biological Origin.
April 2 2014
BIO joins coalition letter to Chairman Patrick Leahy and Ranking Member Chuck Grassley expressing serious concerns with the direction of patent legislation.
February 25 2014
BIO appreciates the opportunity to participate in the Special 301 process and is hopeful that our contribution will assist the United States Trade Representative’s (USTR) efforts in preserving strong intellectual property protections for United States’ companies internationally. BIO appreciates the opportunity to comment on 2014 Special 301 Review: Identification of Countries Under Section 182 of the Trade Act of 1974: Request for Public Comment and Announcement of Public Hearing.
February 24 2014
Lila Feisee, Vice President of International Affairs testified on behalf of BIO and its 1100 members who innovate in the healthcare, agriculture, industrial, and environmental sectors. 
November 20 2013
BIO welcomes the opportunity to provide the views of its members on facilitating access to genetic resources and traditional knowledge and the sharing of benefits from their use...
May 21 2014
BIO applauds Chairman Leahy’s decision to remove the controversial patent bill from the Senate Judiciary Committee’s agenda until greater stakeholder consensus can be achieved.
February 26 2014
Transparent communication important for Patients and Physicians
December 4 2013
BIO and the American Seed Trade Association (ASTA) announced today that the Data Use and Compensation Agreement (DUCA) is open for signature. 
December 3 2013
BIO issued the following statement regarding the Innovation Act (H.R. 3309), as reported by the House Judiciary Committee.
June 13 2013
The SCOTUS decision represents a departure from judicial and PTO precedent supporting patentability of DNA molecules. The decision could create business uncertainty for a range of inventions.